Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancer

28 Aug 2025

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Research and Treatments
Share to Immunodeficiency and Autoimmune Disorders
Share to Veterinary Oncology Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 40882634
DOI: 10.1016/j.ccell.2025.07.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of a STAT3-targeted cyclic oligonucleotide: From murine models to a phase 1 clinical trial in pet cats with oral cancerPMID 40882634Read ↗

Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.Semantic proximity Read ↗

First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer TherapySemantic proximity Read ↗

Comprehensive Live-cell Imaging Analysis of Cryptotanshinone and Synergistic Drug-Screening Effects in Various Human and Canine Cancer Cell LinesSemantic proximity Read ↗

Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcomaSemantic proximity Read ↗

Life-Saving, Dose-Adjusted, Targeted Therapy in a Patient with a STAT3 Gain-of-Function MutationSemantic proximity Read ↗

Characterization of STAT3 activation and expression in canine and human osteosarcomaSemantic proximity Read ↗

Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer—Drug Carriers MatterSemantic proximity Read ↗

Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.Semantic proximity Read ↗

Targeting Stat3 in cancer therapySemantic proximity Read ↗

Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription FactorSemantic proximity Read ↗

Clinical potential of oligonucleotide-based therapeutics in the respiratory systemSemantic proximity Read ↗

Targeting STAT3 in Cancer with Nucleotide TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.